Table 2.
Results of comprehensive genomic profiling and pathogenic gene variants.
| Gene Variant | All Patients | Malignant Melanoma | NSCLC | |||
|---|---|---|---|---|---|---|
| BRAF | 14 | 45.2% | 14 | 53.8% | 0 | 0.0% |
| NRAS | 12 | 38.7% | 12 | 46.2% | 0 | 0.0% |
| TP53 | 8 | 25.8% | 5 | 19.2% | 2 | 40.0% |
| KRAS | 3 | 9.7% | 1 | 3.8% | 2 | 40.0% |
| ARID2 | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% |
| CDKN2A | 3 | 9.7% | 3 | 11.5% | 0 | 0.0% |
| CTNNB1 | 2 | 6.5% | 2 | 7.7% | 0 | 0.0% |
| PTEN | 2 | 6.5% | 0 | 0.0% | 2 | 40.0% |
| ARID1A | 1 | 3.2% | 1 | 3.8% | 0 | 0.0% |
| ATM | 1 | 3.2% | 0 | 0.0% | 1 | 20.0% |
| POLE | 1 | 3.2% | 1 | 3.8% | 0 | 0.0% |
| SF3B1 | 1 | 3.2% | 1 | 3.8% | 0 | 0.0% |
Abbreviation: NSCLC, non-small cell lung cancer.